Generex Biotechnology announced today that its wholly owned subsidiary, Antigen Express, has received Australian Patent No. 778115 titled "Hybrid Peptides Modulate the Immune Response." Antigen Expres
Bionomics Limited announced today that it has filed further patent applications in key markets (including the US) relating to its proprietary cancer drug target BNO69.The role of BNO69 as
Global nanotechnology company pSivida Limited has announced that it has been granted its first patent in China.This first patent grant in China is important as China has the highest incidence
Targeted Genetics Corporation announced today issuance of U.S. patent #6,887,463, entitled, "Methods and Compositions for Gene Therapy for the Treatment of Defects in Lipoprotein Metabolism."
MicroVention announced today that the U.S. Patent and Trademark Office has awarded the company U.S. Patent No. 6,878,384 for its proprietary environmentally-responsive or "smart" hydrogel called
The University of Rochester has filed a patent on several ideas to help prevent early labor and the premature delivery of low-birth-weight babies. The discovery is an incremental step in an area
The University of Rochester has filed a patent on several ideas to help prevent early labor and the premature delivery of low-birth-weight babies. The discovery is an incremental step in an area
Primagen Holding BV has announced that the U.S. Patent and Trademark Office has granted a patent for its Mitox mitochondrial DNA quantification technology as biomarkers for efficacy and adverse events
Neuren Pharmaceuticals has announced that its patent application entitled "GPE Analogs and Peptidomimetics" (PCT/US02/16361) has been issued in the United States (US Patent No: 7,041,314) on 9 May
Shire plc has announced that its subsidiary Shire Laboratories has filed a lawsuit in the U.S. District Court for the District of New Jersey against Corepharma LLC for infringement of some of Shire Labor
The suit alleges that by making, using, and selling the SomatoKine(R) product for the treatment of Growth Hormone Insensitivity Syndrome (GHIS) in the United Kingdom, the companies infringe a European (UK) patent under which Tercica holds an exclusive license. SomatoKine(R) is a complex of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3).
"Tercica's patent portfolio consists of a broad range of patents covering both IGF-1 as well as the combination of IGF-1 and IGFBP-3," said Stephen N. Rosenfield, Tercica's Senior Vice President of Legal Affairs and General Counsel. "This case relates to the infringement of one of our patents for combining IGF-1 and IGFBP-3 for the treatment of short stature, and on October 18, 2004, we sent our first letter demanding that the infringing activities be stopped in the United Kingdom."
On December 17, 2004, Tercica sent a letter to Insmed demanding that Insmed immediately cease and desist from any activity in the United States that constitutes an infringement of Tercica's patent rights under three issued U.S. patents.
http://www.tercica.com/